Beiersdorf: Nivea Turnaround ‘Progressing’ Despite 4.9% Organic Sales Drop
Beiersdorf continues tailoring Nivea’s innovation strategy to local market trends as the brand’s third-quarter organic sales fell 4.9%, while its Derma business growth accelerates.
HBW Insight - October 27, 2026

US FDA Plans Pilot Program For OTC Switches, Other Nonprescription Drugs
FDA soon will launch pilot giving OTC drug sponsors early, structured talks with agency, which should help efforts to encourage more Rx-to-OTC switches.
HBW Insight - October 27, 2026

Vanda Plans Nereus Filing For GLP-1 Adjacent Indication
A Phase III trial showed the NK-1 receptor antagonist helped reduce GLP-1-induced vomiting, and the company plans to file an sNDA with the US FDA.
Scrip - October 27, 2026

Lilly’s Oncology Chief On Leap Of Faith In KRAS, Building An In Vivo-CAR-T Lead
In the first instalment of Scrip’s two-part video interview, Lilly’s Jacob Van Naarden discusses its key presentations at ESMO, and its push to take the lead in KRAS G12C-mutant lung cancer and in vivo CAR-T therapies.
Scrip - October 27, 2026

People On The Move: Appointments At Haleon, Sanotact, IADSA
A round-up of the latest moves in Europe's consumer health sector: Haleon appoints general manager for the Nordics; Sanotact names director for Germany; chair of the IADSA Company Council elected.
HBW Insight - October 27, 2026

Is It Time To Phase Out ‘Women’s Health’?
‘Women’s health’ offers a distinct medical term for half the global population, but is it causing more harm than good? Some industry spectators believe the label has a shelf life.
In Vivo - October 27, 2026

Teva Seals Trump Administration API Deal With MFN Pricing Pledge
Teva joins US efforts to strengthen the domestic supply chain, as it finalizes a governmental deal to donate API for key products, as well as pricing commitments for Medicaid and MFN policies for applicable future innovative launches.
Generics Bulletin - October 27, 2026

Stock Watch: Why Roche Went Down When Its Sales Went Up
Better headline sales growth than Johnson & Johnson the previous week should have been well-received by Roche’s investors. But the layers of a nine-month view, foreign exchange effects and biosimilar erosion left questions on the nature of that growth.
Scrip - October 27, 2026

Cosette Pharmaceuticals Gets FDA Nod For Liquid Oral Formulation Of Evoxac
As eight generic companies continue to compete for market share of Evoxac capsules, Cosette is now listed in the Orange Book as the only approved provider of a liquid oral formulation, following approval through the 505(b)(2) pathway.
Generics Bulletin - October 27, 2026

Novartis Calls Avidity ‘Bump’ Normal, Sticks To Bolt-On M&A Strategy
Novartis CEO Vas Narasimhan backs the company’s current M&A strategy, which is mainly focused on bolt-on deals under $2bn.
Scrip - October 27, 2026

Who’s Hired? Lupin Lifts Legal Leader From Teva
Lupin has looked to Teva to recruit its new chief legal officer. Meanwhile, Fresenius Kabi has a new biopharma business development lead; Centrient has named a new CFO; and Pharmanovia has appointed a new head of medical affairs.
Generics Bulletin - October 27, 2026

ABHI Conference 2026: UK Medtech Wants MHRA To Become ‘A High-Performing Regulator’
Two weeks out from ABHI’s annual conference for the UK medtech industry, Steve Lee, executive director of regulation at the association, offered his views on key regulatory turning points for innovators and patients.
Medtech Insight - October 27, 2026

Brainomix’s AI-Powered Precision Medicine Stroke Offering Targets Non-Specialist Centers
AI technology can directly address the unmet need whereby most sufferers of a stroke are not taken to a central stroke treatment hub but to a spoke site for their initial care. Brainomix CMO George Harston explained the problem and the solution at the annual CPI meeting in London in October.
In Vivo - October 27, 2026

Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans
In this episode of Strategic Intent, David Evans, Partner at Sofinnova Partners, discusses his transition from Roche Venture Fund, different investment strategies, provides a general market analysis across Europe and US, and looks at growing therapeutic area trends within biotech.
In Vivo - October 27, 2026

ESMO 2026: PFS Win For Chia Tai Tianqing’s Pioneering Bispecific In HER2-Low Breast Cancer
Chia Tai Tianqing’s first-in-class anti-HER2 bispecific rolditamig deuderuxtecan (TQB2102) shows 71% reduction in risk of disease progression in HER2-low breast cancer in Phase III data presented at ESMO.
Scrip - October 27, 2026

ESMO 2026: Genfleet Full Speed Ahead On Rasonque Rival After Competitive Early Results
Genfleet’s pan-RAS (ON) inhibitor GFH276 is expected to advance into two late-stage studies in pancreatic ductal adenocarcinoma in the coming months in China.
Scrip - October 27, 2026

US Industry Again Asking Why A Federal Agency Won’t Keep Separate Dietary Supplements Office?
Supplement industry groups oppose National Institutes of Health’s proposal to move Office of Dietary Supplements to be part of the Office of Nutrition Research, which would be moved to the Division of Program Coordination, Planning, and Strategic Initiatives.
HBW Insight - October 27, 2026

Beauty Marketers Risk Consumer Backlash, Regulatory Scrutiny When AI Overpromises In Ads – NAD
Brands that use AI to polish product performance visuals or that include synthetic figures in ads risk turning off shoppers and drawing regulatory or legal scrutiny if the visuals oversell what a product can do, says the National Advertising Division.
HBW Insight - October 27, 2026